Abstract
Purpose :
To compare the long-term clinical outcomes after intravitreal bevacizumab (IVB) injections or photodynamic therapy (PDT) for myopic choroidal neovascularization (CNV) through 7 years follow-up.
Methods :
In this retrospective comparative case series, a total of 37 eyes with 37 patients which were treated with IVB (17 eyes) or PDT (20 eyes) were included. Preoperative classification for myopic maculopathy was made according to the international photographic classification. The primary outcome was the mean change of best-corrected visual acuity (BCVA) between two groups from the baseline through 7 years follow-up.
Results :
The mean change of BCVA from baseline to 7 years follow-up was greater in the IVB group compared with the PDT group (-0.177±0.316 vs. 0.091±0.417 logMAR, P = 0.044). The BCVA from baseline through 7 years follow-up improved in the IVB group (0.642 ± 0.427 vs. 0.463 ± 0.439 logMAR, P = 0.029), but did not improve in the PDT group (0.645 ± 0.402 vs. 0.736 ± 0.576 logMAR, P = 0.266). In subgroup-analysis with 18 eyes with preoperative tessellated fundus only (category 1), there was no difference in improvement of BCVA (-0.338 ± 0.277 vs. -0.156 ± 0.184 logMAR, P = 0.166) and progression of CRA (0.17 ± 0.47 vs. 0 mm2, P = 0.264), CSFT (250.3±14.6 vs. 247.8±38.8 µm, P = 0.929) and SFCT (140.6±74.8 vs. 146.3±104.9 µm, P = 0.929) between two groups at 7 years follow-up. However, 17 eyes with preoperative diffuse CRA (category 2) showed no change of BCVA in IVB group, but decreased BCVA in PDT group (-0.033 ± 0.289 vs. 0.338 ± 0.105 logMAR, P = 0.03). Although, the CSFT was not different between groups (237.7 ± 61.6 vs. 197.8 ± 55.4 µm, P = 0.171), the progression of CRA (1.88 ± 2.89 vs. 6.43 ± 4.44 mm2, P = 0.019) and thinned SCFT (44.3 ± 38.2 vs. 16.9 ± 16.3 µm, P = 0.028) was less in IVB group compared with PDT group.
Conclusions :
The mean change of BCVA was superior in eyes treated with IVB compared to PDT for 7 years follow-up. Additionally, the decreased BCVA and the progression of CRA after PDT treatment were more prominent in eyes with preoperative diffuse CRA (category 2) compared with IVB injections.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.